Biologics in Dermatology

Biomedical and Market Issues Surrounding the Advent of Biosimilars

As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.

Is cosmetic platelet-rich plasma a drug to be regulated by the Food and Drug Administration?

In the area of cosmetic dermatology, some physicians have been injecting activated platelet-rich plasma into the face to promote cosmesis or using it to enhance fat grafts. However, subtle changes to the federal drug code (21 CFR 1271.1) made in 2004, when applied to activated PRP, purport to make this autologous substance a federally regulated drug requiring an extensive and costly Biologics L...

The new biologics in psoriasis: possible treatments for alopecia areata.

Therapeutics in alopecia areata (AA) have remained relatively unchanged for many years, with few treatments having more than moderate effects in severely affected patients. The advent of the new biologic medications in the dermatologic world, however, particularly in psoriasis treatment, introduces possibilities of treatment for many other immune-mediated diseases.

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses

INTRODUCTION The objective of this review was to conduct a systematic review with meta-analysis and Bayesian mixed treatment comparisons (MTC) evaluating the impact of biologics on non-Psoriasis Area and Severity Index (PASI) health outcomes in patients with moderate-to-severe plaque psoriasis. METHODS MEDLINE and Cochrane Central Register of Controlled Trials were searched from 1966 to May 2...

A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics